RAS Mutations Can Predict Resistance To Vectibix, FOLFOX Combination Treatment
Phase II Study Meets Primary Endpoint, Demonstrating Overall Survival of 5.2 Months
ODAC Votes 13:0 For Approving Perjeta
Early Treatment with CMX001 Can Help Prevent CMV Infection
Researchers Identify Mutation Linked to Inherited Risk of ALL
Drug Combination Can Block Proteins Preventing Cell Death In Acute Lymphoblastic Leukemia
Avoiding the Hippocampus During Whole-Brain Radiotherapy Can Preserve Memory Function
Stereotactic Radiosurgery Improves Survival Without Whole-Brain Radiotherapy
Long-term Hormonal Therapy Adds No Additional Benefits
NCI CTEP Approved Trials For the Month of September
FDA Approves Generic Version Of Capecitabine for Metastatic Colorectal and Breast Cancer
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Michael Bishop, Nobel-winning cancer researcher, dies at 90
- A new working group will conduct site visits and advise NCAB and NCI director on cancer center grants
- Roy Herbst named director at Dartmouth Cancer Center
- In the era of immunotherapy, response rate alone fails to predict true patient benefit
Regulators must adapt - FDA issues warning letter to ImmunityBio over misleading claims about cancer drug
